Kronos Bio Inc. Stock News

Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious d

Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma Posters also feature data from preclinical chordoma and sarcoma models KB-0742 is being evaluated in an ongoing Phase 1/2 trial

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conference, a virtual event taking place March 7-9, 2022.

Kronos Bio (NASDAQ: KRON ) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Kronos Bio missed estimated earnings by 2.73%, reporting an EPS of … Full story available on Benzinga.com

Kronos Bio press release (KRON): Q4 GAAP EPS of -$1.13 misses by $0.03.$339.5 million in cash, cash equivalents and investments as of December 31, 2021, providing expected runway…

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Kronos Bio, Inc. (NASDAQ:KRON) shares gapped down before the market opened on Tuesday . The stock had previously closed at $14.00, but opened at $13.70. Kronos Bio shares last traded at $14.66, with a volume of 1,131 shares trading hands. Several analysts recently commented on KRON shares. Zacks Investment Research raised Kronos Bio from a […] The post Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00 appeared first on ETF Daily News .

Kronos Bio, Inc. (NASDAQ:KRON) VP Jorge Dimartino sold 16,402 shares of the firms stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $12.37, for a total value of $202,892.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through []

Oncorus (NASDAQ:ONCR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 79.6% of Oncorus shares are held by institutional investors. Comparatively, 68.3% of []

Kronos Bio, Inc. (NASDAQ:KRON) CEO Norbert W. Bischofberger acquired 14,356 shares of the firms stock in a transaction dated Monday, December 6th. The stock was bought at an average cost of $12.09 per share, with a total value of $173,564.04. The transaction was disclosed in a document filed with the SEC, which is available at []

Related Stocks: KRON ,

Data in the second half of 2023 could potentially lead to accelerated approval If approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for intensive induction

Kronos Bio, Inc. gapped up prior to trading on Wednesday. The stock had previously closed at $11.81, but opened at $12.35. Kronos Bio shares last traded at $11.87, with a

Kronos Bio, Inc. (NASDAQ:KRON) gapped up prior to trading on Wednesday . The stock had previously closed at $11.81, but opened at $12.35. Kronos Bio shares last traded at $11.87, with a volume of 71 shares changing hands. Several analysts recently issued reports on KRON shares. Cowen started coverage on Kronos Bio in a report [] The post Kronos Bio (NASDAQ:KRON) Shares Gap Up to $11.81 appeared first on ETF Daily News .